Authors : Thilagavathi K.; Sivakumar G.; Narmatha K. K.; Deepika A.; Keerthana S.; Evania Helen M. D.

Volume/Issue : Volume 11 - 2026, Issue 9 - September

Google Scholar : https://tinyurl.com/2tu7ymt7

DOI : https://doi.org/10.38124/ijisrt/26sep1305

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Parkinson's disease is a progressive neurodegenerative condition marked by the loss of dopaminergic neurons, mitochondrial dysfunction, oxidative stress, and persistent neuroinflammation. Recent findings suggest that impaired glucose metabolism and disrupted energy balance may play a role in the early stages of the disease's progression. In light of this, therapies based on metabolic hormones have garnered interest for their potential neuroprotective effects. Retatrutide, a new triple agonist that targets GLP-1, GIP, and glucagon receptors, offers a promising therapeutic approach. The activation of these receptors influences crucial intracellular pathways that are involved in neuronal survival, reducing inflammation, and enhancing mitochondrial function. Preclinical research on incretin-based therapies has shown a decrease in dopaminergic neurodegeneration and improvements in motor function. This review delves into the impact of metabolic dysfunction in Parkinson’s disease and assesses the therapeutic promise of multi-receptor agonists, with a particular focus on Retatrutide. Although the findings are encouraging, additional clinical studies are necessary to confirm its effectiveness and safety in neurodegenerative diseases.

Keywords : Parkinson’s Disease, Retatrutide, Incretin Based Therapy, Neuroprotection, Mitochondrial Dysfunction, Neuroinflammation.

References :

1. Zde Lau LM, Refsum H, Smith AD, Johnston C, Breteler MM. P1–205: Folate levels and cognitive performance. The Rotterdam Scan Study. Alzheimer's & Dementia. 2006 Jul 1;2(3):S156.
2. Dunn TJ, Baguley T, Brunsden V. From alpha to omega: A practical solution to the pervasive problem of internal consistency estimation. British journal of psychology. 2014 Aug;105(3):399-412.
3. Bassil C. The Effect of Terrorism on Tourism Demand in the Middle East. Peace Economics, Peace Science, & Public Policy. 2014 Dec 1;20(4).
4. Windram M, Lovelock DF, Carew JM, Krieman CG, Hendershot CS, Besheer J. Semaglutide, tirzepatide, and Retatrutide attenuate the interoceptive effects of alcohol in male and female rats. Psychopharmacology. 2025 Jul 23:1-3.
5. Mosconi L, Berti V, Glodzik L, Pupi A, De Santi S, de Leon MJ. Pre-clinical detection of Alzheimer’s disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis. 2010;20(3):843–54.
6. Femminella GD, Edison P. Evaluation of neuroprotective effect of glucagon-like peptide 1 analogs using neuroimaging. Alzheimer’s Dement J Alzheimer’s Assoc. 2014;10(1 Suppl):S55-61.
7. Athauda D, Evans J, Wernick A, Virdi G, Choi ML, Lawton M, et al. The impact of type 2 diabetes in Parkinson’s disease. Mov Disord. 2022;37(8):1612–23.
8. Cheong JLY, de Pablo-Fernandez E, Foltynie T, Noyce AJ. The association between type 2 diabetes mellitus and Parkinson’s disease. J Parkinson’s Dis. 2020;24(10):775–89.
9. Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J. Type 2 diabetes and the risk of Parkinson’s disease. Diabetes Care.2007;30(4):842–7.
10. Yuan Y, Zhao G, Zhao Y. Dysregulation of energy metabolism in Alzheimer’s disease. J Neurol. 2024;272(1):2.
11. Devi, L.; Raghavendran, V.; Prabhu, B.M.; Avadhani, N.G.; Anandatheerthavarada, H.K. Mitochondrial import and accumulation of α-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem. 2008, 283, 9089–9100.
12. Narendra, D.P.; Jin, S.M.; Tanaka, A.; Suen, D.F.; Gautier, C.A.; Shen, J.; Cookson, M.R.; Youle, R.J. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol. 2010, 8, e1000298.
13. Pickles, S.; Vigié, P.; Youle, R. Mitophagy and Quality Control Mechanisms in Mitochondrial Maintenance. Curr. Biol. 2018, 28, R170–R185.
14. Malpartida, A.; Williamson, M.; Narendra, D.; Wade-Martins, R.; Ryan, B. Mitochondrial Dysfunction and Mitophagy in Parkinson’s Disease: From Mechanism to Therapy. Trends Biochem. Sci. 2021, 46, 329–343.
15. Swatek, K.; Usher, J.; Kueck, A.; Gladkova, C.; Mevissen, T.; Pruneda, J.; Skern, T.; Komander, D. Insights into ubiquitin chain architecture using Ub-clipping. Nature 2019, 572, 533–537.
16. Wauer, T.; Simicek, M.; Schubert, A.; Komander, D. Mechanism of phospho-ubiquitin-induced PARKIN activation. Nature 2015, 524, 370–374.
17. Gladkova, C.; Maslen, S.; Skehel, J.; Komander, D. Mechanism of parkin activation by PINK1. Nature 2018, 559, 410–414.
18. Harper, J.; Ordureau, A.; Heo, J. Building and decoding ubiquitin chains for mitophagy. Nat. Rev. Mol. Cell Biol. 2018, 19, 93–108.
19. Hou, X.; Fiesel, F.; Truban, D.; Castanedes Casey, M.; Lin, W.; Soto, A.; Tacik, P.; Rousseau, L.; Diehl, N.; Heckman, M.; et al. Ageand disease-dependent increase of the mitophagy marker phospho-ubiquitin in normal aging and Lewy body disease. Autophagy 2018, 14, 1404–1418.
20. Fiesel, F.; Ando, M.; Hudec, R.; Hill, A.; Castanedes-Casey, M.; Caulfield, T.; Moussaud-Lamodière, E.; Stankowski, J.; Bauer, P.; Lorenzo-Betancor, O.; et al. (Patho-)physiological relevance of PINK1-dependent ubiquitin phosphorylation. EMBO Rep. 2015, 16, 1114–1130.
21. Hsieh, C.; Shaltouki, A.; Gonzalez, A.; Bettencourt da Cruz, A.; Burbulla, L.; St Lawrence, E.; Schüle, B.; Krainc, D.; Palmer, T.; Wang, X. Functional Impairment in Miro Degradation and Mitophagy Is a Shared Feature in Familial and Sporadic Parkinson’s Disease. Cell Stem Cell 2016, 19, 709–724.
22. Godena, V.; Brookes-Hocking, N.; Moller, A.; Shaw, G.; Oswald, M.; Sancho, R.; Miller, C.; Whitworth, A.; De Vos, K. Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations. Nat. Commun. 2014, 5, 5245.
23. Bonello, F.; Hassoun, S.; Mouton-Liger, F.; Shin, Y.; Muscat, A.; Tesson, C.; Lesage, S.; Beart, P.; Brice, A.; Krupp, J.; et al. LRRK2 impairs PINK1/Parkin-dependent mitophagy via its kinase activity: Pathologic insights into Parkinson’s disease. Hum. Mol. Genet. 2019, 28, 1645–1660.
24. Wauters, F.; Cornelissen, T.; Imberechts, D.; Martin, S.; Koentjoro, B.; Sue, C.; Vangheluwe, P.; Vandenberghe, W. LRRK2 mutations impair depolarization-induced mitophagy through inhibition of mitochondrial accumulation of RAB10. Autophagy 2020, 16, 203–222.
25. Liu, Y.; Huang, X.; Nguyen, D.; Shammas, M.; Wu, B.; Dombi, E.; Springer, D.; Poulton, J.; Sekine, S.; Narendra, D. Loss of CHCHD2 and CHCHD10 activates OMA1 peptidase to disrupt mitochondrial cristae phenocopying patient mutations. Hum. Mol. Genet. 2020, 29, 1547–1567.
26. Cornelissen, T.; Spinazzi, M.; Martin, S.; Imberechts, D.; Vangheluwe, P.; Bird, M.; De Strooper, B.; Vandenberghe, W. CHCHD2 harboring Parkinson’s disease-linked T61I mutation precipitates inside mitochondria and induces precipitation of wild-type CHCHD2. Hum. Mol. Genet. 2020, 29, 1096–1106.
27. Meng, H.; Yamashita, C.; Shiba-Fukushima, K.; Inoshita, T.; Funayama, M.; Sato, S.; Hatta, T.; Natsume, T.; Umitsu, M.; Takagi, J.; et al. Loss of Parkinson’s disease-associated protein CHCHD2 affects mitochondrial crista structure and destabilizes cytochrome c. Nat. Commun. 2017, 8, 15500.
28. Ikeda, A.; Nishioka, K.; Meng, H.; Takanashi, M.; Hasegawa, I.; Inoshita, T.; Shiba-Fukushima, K.; Li, Y.; Yoshino, H.; Mori, A.; et al. Mutations in CHCHD2 cause α-synuclein aggregation. Hum. Mol. Genet. 2019, 28, 3895–3911.
29. Athauda D, Wyse R, Brundin P, Foltynie T. Is exenatide a treatment for Parkinson’s disease? . Journal of Parkinson’s Disease. 2017 Aug 8;7(3):451-8.
30. Bertilsson E. Lärarna på skolans kungsväg: Om det naturvetenskapliga programmet på några gymnasier i Uppsala. SEC, EDU, Uppsala universitet; 2007.
31. Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. Journal of neuroinflammation. 2008 May 21;5(1):19.
32. Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geghman K, Bogdanov M, Przedborski S, Beal MF. Mutant LRRK2 R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nature neuroscience. 2009 Jul;12(7):826-8.
33. Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, Cousens S, Mathers C, Black RE. Global, regional, and national causes of child mortality in 2000–13, with projections to inform post-2015 priorities: an updated systematic analysis. The lancet. 2015 Jan 31;385(9966):430-40.
34. Kim JI, Ju YS, Park H, Kim S, Lee S, Yi JH, Mudge J, Miller NA, Hong D, Bell CJ, Kim HS. A highly annotated whole-genome sequence of a Korean individual. nature. 2009 Aug;460(7258):1011-5.
35. Yun SP, Kam TI, Panicker N, Kim S, Oh Y, Park JS, Kwon SH, Park YJ, Karuppagounder SS, Park H, Kim S. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease. Nature medicine. 2018 Jul;24(7):931-8.
36. Nowell J, Blunt E, Gupta D, Edison P. Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease. Ageing research reviews. 2023 Aug 1;89:101979.
37. Alharbi SH. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Therapeutic Advances in Endocrinology and Metabolism. 2024 Jan;15:20420188231222367.
38. Bertilsson, G.; Patrone, C.; Zachrisson, O.; Andersson, A.; Dannaeus, K.; Heidrich, J.; Kortesmaa, J.; Mercer, A.; Nielsen, E.; Rönnholm, H.; et al. Peptide Hormone Exendin-4 Stimulates Subventricular Zone Neurogenesis in the Adult Rodent Brain and Induces Recovery in an Animal Model of Parkinson’s Disease. J. Neurosci. Res. 2008, 86, 326–338.
39. Feng P, Zhang X, Li D, Ji C, Yuan Z, Wang R, Xue G, Li G, Hölscher C. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease. Neuropharmacology. 2018 May 1;133:385-94.
40. Zhang ZQ, Hölscher C. GIP has neuroprotective effects in Alzheimer and Parkinson’s disease models. Peptides. 2020 Mar 1;125:170184.
41. Li Y, Liu W, Li L, Hölscher C. Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model. Neuropharmacology. 2016 Feb 1;101:255-63.
42. Finan B, Ma T, Ottaway N, Müller TD, Habegger KM, Heppner KM, Kirchner H, Holland J, Hembree J, Raver C, Lockie SH. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Science translational medicine. 2013 Oct 30;5(209):209ra151-.
43. Hölscher C. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models. Neuropharmacology. 2018 Jul 1;136:251-9.
44. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell metabolism. 2013 Jun 4;17(6):819-37.
45. Athauda D, Foltynie T. Insulin resistance and Parkinson’s disease: a new target for disease modification?. Progress in neurobiology. 2016 Oct 1;145:98-120.
46. Schapira AH. Mitochondrial dysfunction in Parkinson's disease. Cell Death & Differentiation. 2007 Jul 1;14(7).
47. Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O’Farrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism. 2022 Sep 6;34(9):1234-47.
48. Hölscher C. Insulin signaling impairment in the brain as a risk factor in Alzheimer’s disease. Frontiers in aging neuroscience. 2019 Apr 24;11:88.
49. Li Y, Liu W, Li L, Hölscher C. D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation. European journal of pharmacology. 2017 Feb 15;797:162-72.
50. Hölscher C. Incretin Hormones GLP-1 and GIP Normalize Energy Utilization and Reduce Inflammation in the Brain in Alzheimer’s Disease and Parkinson’s Disease: From Repurposed GLP-1 Receptor Agonists to Novel Dual GLP-1/GIP Receptor Agonists as Potential Disease-Modifying Therapies: C. Hölscher. CNS drugs. 2025 Dec;39(12):1201-20.
51. Hölscher C. Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders. British journal of pharmacology. 2022 Feb;179(4):695-714.
52. Zhang L, Zhang L, Li Y, Li L, Melchiorsen JU, Rosenkilde MM, et al. The neuroprotective effects of GLP-1 receptor agonists in Parkinson’s disease.
53. Li T, Tu L, Gu R, Yang XL, Liu XJ, Zhang GP, Wang Q, Ren YP, Wang BJ, Tian JY. Neuroprotection of GLP-1/GIP receptor agonist via inhibition of mitochondrial stress by AKT/JNK pathway in a Parkinson's disease model. Life sciences. 2020 Sep 1;256:117824.
54. Finan B, Clemmensen C, Müller TD. Emerging opportunities for the treatment of metabolic diseases: glucagon-like peptide-1 based multi-agonists. Molecular and Cellular Endocrinology. 2015 Dec 15;418:42-54.
55. Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML. Triple–hormone-receptor agonist Retatrutide for obesity—a phase 2 trial. New England Journal of Medicine. 2023 Aug 10;389(6):514-26
56. Finan B, Yang B, Ottaway N, Smiley DL, Ma T, Clemmensen C, Chabenne J, Zhang L, Habegger KM, Fischer K, Campbell JE. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nature medicine. 2015 Jan;21(1):27-36.
57. Müller TD, Finan B, Clemmensen C, DiMarchi RD, Tschöp MH. The new biology and pharmacology of glucagon. Physiological reviews. 2017 Apr;97(2):721-66.
58. Glotfelty EJ, Olson L, Karlsson TE, Li Y, Greig NH. Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson’s disease. Expert Opinion on Investigational Drugs. 2020 Jun 2;29(6):595-602.
59. Kopp KO, Li Y, Glotfelty EJ, Tweedie D, Greig NH. Incretin-based multi-agonist peptides are neuroprotective and anti-inflammatory in cellular models of neurodegeneration. Biomolecules. 2024 Jul 19;14(7):872.
60. Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML. Triple–hormone-receptor agonist Retatrutide for obesity—a phase 2 trial. New England Journal of Medicine. 2023 Aug 10;389(6):514-26.
61. Athauda D, Greig NH, Meissner WG, Foltynie T, Gandhi S. The promise of GLP-1 receptor agonists for neurodegenerative diseases. The Journal of Clinical Investigation. 2026 Feb 16;136(4).
62. Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. The Lancet. 2018 Nov 17;392(10160):2180-93.
63. Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, Whitton P, Wyse R, Isaacs T, Lees A, Limousin P. Exenatide and the treatment of patients with Parkinson’s disease. The Journal of clinical investigation. 2013 Jun 3;123(6):2730-6.
64. Meier JJ, Nauck MA. Incretin-based therapies: where will we be 50 years from now?. Diabetologia. 2015 Aug;58(8):1745-50.;
65. Meredith ME, Salameh TS, Banks WA. Intranasal delivery of proteins and peptides in the treatment of neurodegenerative diseases. The AAPS journal. 2015 Jul;17(4):780-7.
66. Duty S, Jenner P. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. British journal of pharmacology. 2011 Oct;164(4):1357-91.
67. Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. The Lancet. 2017 Oct 7;390(10103):1664-75.
68. Athauda D, Foltynie T. Challenges in detecting disease modification in Parkinson's disease clinical trials. Parkinsonism & related disorders. 2016 Nov 1;32:1-1.
69. De Pablo-Fernández E, Breen DP, Bouloux PM, Barker RA, Foltynie T, Warner TT. Neuroendocrine abnormalities in Parkinson's disease. Journal of Neurology, Neurosurgery & Psychiatry. 2017 Feb 1;88(2):176-85.
70. Oldfors A. Is glycogenin essential for glycogen synthesis?.Cell Metabolism. 2017 Jul 5;26(1):12-4.
71. Vegas AJ, Veiseh O, Gürtler M, Millman JR, Pagliuca FW, Bader AR, Doloff JC, Li J, Chen M, Olejnik K, Tam HH. Long-term glycemic control using polymer-encapsulated human stem cell–derived beta cells in immune-competent mice. Nature medicine. 2016 Mar;22(3):306-11.